Login / Signup

SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC).

Amy D ProalMichael B VanElzakkerSoo AlemanKatie BachBrittany P BoribongMarcus BuggertSara CherryDaniel S ChertowHelen E DaviesChristopher L DupontSteven G DeeksWilliam EimerE Wesley ElyAlessio FasanoMarcelo O FreireLinda N GengDiane E GriffinTimothy J HenrichAkiko IwasakDavid Izquierdo-GarciaMichela LocciSaurabh MehandruMark M PainterMichael J PelusoEtheresia PretoriusDavid A PriceDavid PutrinoRichard H ScheuermannGene S TanRudolph E TanziHenry F VanBrocklinLael M YonkerE John Wherry
Published in: Nature immunology (2023)
Millions of people are suffering from Long COVID or post-acute sequelae of COVID-19 (PASC). Several biological factors have emerged as potential drivers of PASC pathology. Some individuals with PASC may not fully clear the coronavirus SARS-CoV-2 after acute infection. Instead, replicating virus and/or viral RNA-potentially capable of being translated to produce viral proteins-persist in tissue as a 'reservoir'. This reservoir could modulate host immune responses or release viral proteins into the circulation. Here we review studies that have identified SARS-CoV-2 RNA/protein or immune responses indicative of a SARS-CoV-2 reservoir in PASC samples. Mechanisms by which a SARS-CoV-2 reservoir may contribute to PASC pathology, including coagulation, microbiome and neuroimmune abnormalities, are delineated. We identify research priorities to guide the further study of a SARS-CoV-2 reservoir in PASC, with the goal that clinical trials of antivirals or other therapeutics with potential to clear a SARS-CoV-2 reservoir are accelerated.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • immune response
  • clinical trial
  • water quality
  • liver failure
  • coronavirus disease
  • dendritic cells
  • drug induced
  • amino acid
  • protein protein